Literature DB >> 23324887

Effects of a TREM-like transcript 1-derived peptide during hypodynamic septic shock in pigs.

Marc Derive1, Amir Boufenzer, Youcef Bouazza, Frédérique Groubatch, Corentine Alauzet, Damien Barraud, Alain Lozniewski, Pierre Leroy, Nguyen Tran, Sébastien Gibot.   

Abstract

The objective of this study was to determine the effects of a TREM (triggering receptor expressed on myeloid cells 1)-like transcript 1-derived peptide (LR12) administration during septic shock in pigs. Two hours after induction of a fecal peritonitis, anesthetized and mechanically ventilated adult male minipigs were randomized to receive LR12 (n = 6) or its vehicle alone (normal saline, n = 5). Two animals were operated and instrumented without the induction of peritonitis and served as controls (sham). Resuscitation was achieved using hydroxyethyl starch (up to 20 mL/kg) and norepinephrine infusion (up to 10 μg/kg per minute). Hemodynamic parameters were continuously recorded. Gas exchange, acid-base status, organ function, and plasma cytokines concentrations were evaluated at regular intervals until 24 h after the onset of peritonitis when animals were killed under anesthesia. Peritonitis induced profound hypotension, myocardial dysfunction, lactic acidosis, coagulation abnormalities, and multiple organ failure. These disorders were largely attenuated by LR12. In particular, cardiovascular failure was dampened as attested by a better mean arterial pressure, cardiac index, cardiac power index, and S(v)O(2), despite lower norepinephrine requirements. LR12, a TREM-like transcript 1-derived peptide, exhibits salutary properties during septic shock in adult minipigs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23324887     DOI: 10.1097/SHK.0b013e31827bcdfb

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  20 in total

Review 1.  Triggering receptor expressed on myeloid cells receptor family modulators: a patent review.

Authors:  Christopher J Pelham; Amit N Pandya; Devendra K Agrawal
Journal:  Expert Opin Ther Pat       Date:  2014-11-01       Impact factor: 6.674

2.  A first-in-man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM-1 receptor inhibition.

Authors:  Valerie Cuvier; Ulrike Lorch; Stephan Witte; Aurelie Olivier; Sebastien Gibot; Isabelle Delor; Jean-Jacques Garaud; Marc Derive; Margarita Salcedo-Magguilli
Journal:  Br J Clin Pharmacol       Date:  2018-07-20       Impact factor: 4.335

3.  Nangibotide attenuates osteoarthritis by inhibiting osteoblast apoptosis and TGF-β activity in subchondral bone.

Authors:  Yiming Zhong; Yiming Xu; Song Xue; Libo Zhu; Haiming Lu; Cong Wang; Hongjie Chen; Weilin Sang; Jinzhong Ma
Journal:  Inflammopharmacology       Date:  2022-04-07       Impact factor: 4.473

Review 4.  TREM-1 Modulation Strategies for Sepsis.

Authors:  Sara Siskind; Max Brenner; Ping Wang
Journal:  Front Immunol       Date:  2022-06-15       Impact factor: 8.786

5.  TREM-1 orchestrates angiotensin II-induced monocyte trafficking and promotes experimental abdominal aortic aneurysm.

Authors:  Marie Vandestienne; Yujiao Zhang; Icia Santos-Zas; Rida Al-Rifai; Jeremie Joffre; Andreas Giraud; Ludivine Laurans; Bruno Esposito; Florence Pinet; Patrick Bruneval; Juliette Raffort; Fabien Lareyre; Jose Vilar; Amir Boufenzer; Lea Guyonnet; Coralie Guerin; Eric Clauser; Jean-Sébastien Silvestre; Sylvie Lang; Laurie Soulat-Dufour; Alain Tedgui; Ziad Mallat; Soraya Taleb; Alexandre Boissonnas; Marc Derive; Giulia Chinetti; Hafid Ait-Oufella
Journal:  J Clin Invest       Date:  2021-01-19       Impact factor: 14.808

Review 6.  Novel ligands and modulators of triggering receptor expressed on myeloid cells receptor family: 2015-2020 updates.

Authors:  Harbinder Singh; Vikrant Rai; Sunil K Nooti; Devendra K Agrawal
Journal:  Expert Opin Ther Pat       Date:  2021-02-08       Impact factor: 6.714

Review 7.  Triggering receptor expressed on myeloid cells-1 (TREM-1): a new player in antiviral immunity?

Authors:  Kelsey Roe; Sébastien Gibot; Saguna Verma
Journal:  Front Microbiol       Date:  2014-11-26       Impact factor: 5.640

8.  Blocking triggering receptor expressed on myeloid cells-1 attenuates lipopolysaccharide-induced acute lung injury via inhibiting NLRP3 inflammasome activation.

Authors:  Tian Liu; Yong Zhou; Ping Li; Jia-Xi Duan; Yong-Ping Liu; Guo-Ying Sun; Li Wan; Liang Dong; Xiang Fang; Jian-Xin Jiang; Cha-Xiang Guan
Journal:  Sci Rep       Date:  2016-12-22       Impact factor: 4.379

9.  Effect of TREM-1 blockade and single nucleotide variants in experimental renal injury and kidney transplantation.

Authors:  Alessandra Tammaro; Jesper Kers; Diba Emal; Ingrid Stroo; Gwendoline J D Teske; Loes M Butter; Nike Claessen; Jeffrey Damman; Marc Derive; Gerjan J Navis; Sandrine Florquin; Jaklien C Leemans; Mark C Dessing
Journal:  Sci Rep       Date:  2016-12-08       Impact factor: 4.379

10.  Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial.

Authors:  Bruno Francois; Simon Lambden; Sebastien Gibot; Marc Derive; Aurelie Olivier; Valerie Cuvier; Stephan Witte; Jean-Marie Grouin; Jean Jacques Garaud; Margarita Salcedo-Magguilli; Mitchell Levy; Pierre-François Laterre
Journal:  BMJ Open       Date:  2021-07-07       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.